Skip to main content
Clinical Trials/NCT05483738
NCT05483738Active, not recruitingNot Applicable

The Impact of Mitochondrial Dysfunction on Human Bone Cell Metabolism and Remodelling

Aalborg University Hospital1 site in 1 country30 target enrollmentStarted: February 1, 2020Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
30
Locations
1
Primary Endpoint
Extracellular acidification rate (ECAR) (mpH/min)

Study Overview

Brief Summary

Cell and mice studies suggest mitochondrial dysfunction may cause altered bone structure.

Hypothesis: Decreased mitochondrial energy production affects bone cell development and activity negatively.

Comparing humans with the mitochondrial DNA variant, m.3243A>G, pathogenic variants in POLG or TWNK genes to healthy controls, the aim is to evaluate the effect of mitochondrial dysfunction on: 1: bone-cell development and -activity in bone marrow stem cells and blood.

2: bone cell metabolism including glucose consumption. 3: bone structure assessed by electron microscopy and μCT scans of bone biopsies.

Detailed Description

Intact mitochondrial activity including adequate energy supplies is vital for metabolic active tissues i.e. skeletal muscle, heart and brain. The human skeleton represent an additional highly metabolically active tissue; nevertheless the significance of the mitochondrial role in human skeletal bone health may be further investigated.

Bone remodelling constitutes the coupled and continuous regenerative process of bone degradation by bone resorbing cells osteoclasts (OC) followed by formation of bone matrix by bone forming osteoblasts (OB). Quantitative imbalance between resorption and formation results in skeletal disorders with low bone mass including osteoporosis, and its increased risk of fragility fractures.

Mitochondria generate cellular energy adenosine triphosphate (ATP) through oxidative phosphorylation process (OXPHOS) in the respiratory chain (RC) with a secondary production of the deleterious by-products free radicals i.e. reactive oxygen species (ROS). Notably, mitochondria hold their own DNA (m.DNA), and RC subunits are encoded by m.DNA and nuclear DNA (n.DNA) genes, respectively. With ageing, deleterious somatic m.DNA mutations accumulate in skeletal muscle and heart, and somatic m.DNA mutations as well as inherited m.DNA or n.DNA mutations may result in mitochondrial dysfunction with impaired ATP production and accumulation of ROS. m.DNA mutations may impair brain, skeletal-, and cardiac muscle function, but the effects on human bone cell metabolism and remodelling are unknown. A recent study of a cohort of young individuals indicates that mitochondrial diseases pose a risk for bone fragility fractures.

Preclinical studies suggest that ATP and ROS regulate bone metabolism. The m.DNA number and mitochondrial activity increase to support differentiation from human skeletal (mesenchymal) stem cells (hMSC) to mature bone forming OBs. Inhibition of mitochondrial activity or increase in ROS levels suppress OB differentiation. Similarly, OCs are rich in mitochondria. Human OC cultures demonstrate that energy supplies for OC differentiation from their progenitors is based on OXPHOS while OC resorption activity relies on glycolysis.

In addition, emerging evidence suggest that metabolic plasticity i.e. regulation of glycolysis, OXPHOS, and pyruvate levels, contribute to regulation of OB and OC differentiation.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Basic Science
Masking
None

Masking Description

Participants are masked with anonymized identifier (ID)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Genetic diagnosis with: MT-TL1 m.3243A>G, or POLG variant, het or TWNK variant, het, > 18 years
  • •Signed informed consent
  • •Inclusion Criteria - controls:
  • •Healthy subjects matched on age and gender > 18 years
  • •Signed informed consent

Exclusion Criteria

  • •Renal (creatinine > 90 µmol/l)
  • •Liver dysfunction (AST > 3 times the upper limit)
  • •Medical treatment influencing bone metabolism (oral corticosteroid <12 weeks, anti-osteoporosis treatment, sex steroids, anti-convulsants)
  • •Pregnancy
  • •Excessive consumption of alcohol
  • •Treatment with anticoagulants
  • •Pre-existing coagulopathy
  • •Allergy to lidocaine, morphine or diazepam.

Arms & Interventions

Cases and controls

Other

Clinical assessment, blood samples, dual energy x-ray absorptiometry (DXA) scan, and assessment of bone marrow, and tetracycline labelled bone biopsy

Intervention: Clinical assessment, blood samples, bone marrow and bone biopsy (Diagnostic Test)

Outcomes

Primary Outcomes

Extracellular acidification rate (ECAR) (mpH/min)

Time Frame: Up to 12 weeks

Measurement of ECAR in human bone marrow skeletal (mesenchymal) stem cells (hBM-MSCs), osteoblasts (OB) and osteoclasts (OC)

Growth rate (number of cells)

Time Frame: Up to 12 weeks

Growth rate of of OBs and OCs

Oxygen consumption rate (OCR) (mpMol/min)

Time Frame: Up to 12 weeks

Measurement of OCR in hBM-MSCs, OBs and OCs

Secondary Outcomes

  • Histomorphometric(Up to 4 weeks)
  • Bone growth rate (µm/day)(Up to 4 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Anja Lisbeth Frederiksen

MD, Ph.D, Clinical Professor

Aalborg University Hospital

Study Sites (1)

Loading locations...

Similar Trials